Annexon, Inc. Stock Price, News & Analysis

Annexon (ANNX) has granted a stock option inducement award to a new non-executive employee under its 2022 Employment Inducement Award Plan. The grant was approved on April 11, 2025, complying with Nasdaq Listing Rule 5635(c)(4).

The employee received options to purchase 105,000 shares of Annexon common stock at an exercise price of $1.54 per share, matching the closing price on April 15, 2025. The option has a ten-year term and vests over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.

Aviceda Therapeutics, a clinical-stage biotech company, has appointed Dr. Emmett T. Cunningham Jr. to its Board of Directors. Dr. Cunningham brings over 20 years of experience as a physician-scientist, healthcare entrepreneur, and investor, previously serving as Senior Managing Director at Blackstone Group.

Throughout his career, Dr. Cunningham has contributed to the FDA approval of ten therapeutics, including notable ophthalmic treatments. He previously held the position of Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, where he played a key role in developing Macugen®, the first VEGF-A inhibitor approved for specific eye conditions.

The appointment comes as Aviceda prepares to advance AVD-104 into pivotal trials for geographic atrophy, utilizing their proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform aimed at alleviating chronic, non-resolving inflammation.

Annexon (NASDAQ: ANNX) presented pivotal Phase 3 data for tanruprubart, a potential first targeted therapy for Guillain-Barré Syndrome (GBS), at the AAN 2025 Annual Meeting. The trial of 241 patients demonstrated that a single infusion of tanruprubart led to 2.4-fold higher likelihood of improved health versus placebo at Week 8.

Key findings include: patients showed 14-fold higher mobility at Week 1, twice the number of treated patients had no limitations at Week 26, and patients recovered approximately one month earlier than placebo group. The treatment reduced intensive care time by about a week. A Real World Evidence study comparing tanruprubart with standard treatments (IVIg/PE) showed superior muscle strength recovery.

GBS affects 150,000 people worldwide annually, with no FDA-approved therapies. Annexon also launched the Move GBS Forward™ education campaign to increase disease awareness among healthcare professionals.

Annexon (ANNX) is showcasing its leadership in Guillain-Barré Syndrome (GBS) research at the American Academy of Neurology Annual Meeting 2025. The company will present Phase 3 trial data for ANX005, their potential first targeted therapy for GBS, during an oral plenary session on April 8.

Key highlights include an educational symposium on GBS care and the classical complement pathway, featuring expert presenters from leading medical institutions. Additionally, Annexon is launching 'Move GBS Forward,' a disease education campaign at Booth #2133 to promote awareness of GBS's impact and encourage prompt diagnosis.

GBS affects approximately 150,000 people worldwide annually and currently has no FDA-approved therapies. ANX005, a first-in-kind monoclonal antibody, is designed to block C1q with a single infusion to stop neuroinflammation and nerve damage during acute GBS phases.

Annexon (ANNX) has granted stock options to a new non-executive employee as part of its 2022 Employment Inducement Award Plan. The equity award, approved on March 12, 2025, complies with Nasdaq Listing Rule 5635(c)(4).

The grant includes options to purchase 35,000 shares of Annexon common stock with a ten-year term and an exercise price of $2.60 per share, matching the closing price on March 14, 2025. The options vest over 4 years, with 25% vesting after the first year and the remaining 1/48th vesting monthly thereafter, contingent on continued employment.

Annexon (NASDAQ: ANNX) reported its Q4 and full-year 2024 financial results, highlighting progress across its late-stage clinical platform. The company maintains a strong financial position with $312 million in cash and investments as of December 31, 2024, providing runway into H2 2026.

Key developments include:

• ANX005 for Guillain-Barré Syndrome (GBS) advancing toward pre-BLA meeting in H1 2025
• Established global registration path for ANX007 as potential first vision-preserving treatment for dry AMD with GA
• Ongoing proof-of-concept trial for ANX1502, first-in-kind oral C1s inhibitor

Financial results show R&D expenses of $43.4M for Q4 2024 ($119.4M full-year), compared to $23.3M in Q4 2023 ($113.8M full-year). Net loss was $48.6M for Q4 2024 ($138.2M full-year), versus $27.9M in Q4 2023 ($134.2M full-year).

Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

The company's president and CEO, Douglas Love, will deliver a presentation on March 4, 2025, at 11:50 a.m. EST. Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section on Annexon's Investors page. The presentation recording will remain available on the company's website for 30 days afterward.

Annexon (ANNX) has granted stock options to six new non-executive employees as part of its 2022 Employment Inducement Award Plan. The equity awards, approved on February 10, 2025, comply with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase a total of 542,000 shares of Annexon common stock at an exercise price of $3.07 per share, matching the closing price on February 14, 2025.

The options have a ten-year term and vest over four years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.

Annexon (NASDAQ: ANNX) announced presentations highlighting their ANX007 treatment for geographic atrophy (GA) at the Macula Society 48th Annual Meeting. ANX007, a first-in-kind, non-pegylated antigen-binding fragment, is designed to block C1q locally in the eye through intravitreal formulation.

The treatment has demonstrated significant vision preservation in best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), along with preservation of central retinal photoreceptors. Two presentations are scheduled for February 13, 2025: Dr. Rahul Khurana will discuss the impact of C1q inhibition on visual acuity protection, while Dr. Eleonora Lad will present on C1q inhibition's role in attenuating microglia-induced neuronal injury.